1-3 of 3
Kathryn Parker
Close
Sort by
Journal Articles

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

Daniel J. DeAngelo, MD, PhD, Andrew Spencer, Thomas Fischer, MD, Thomas Kindler, MD, Oliver G. Ottmann, MD, Miles Prince, MD, Frank J. Giles, MD, MB, FRCPI, FRCPath, Jorge Cortes, MD, Angela Liu, PharmD, Kathryn Parker, PhD, Ying Yan, Jeffrey W. Scott, Kapil N. Bhalla, MD
Journal: Blood
Blood (2009) 114 (22): 2898.
https://doi.org/10.1182/blood.V114.22.2898.2898
Published: 2009
Journal Articles

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, MD, Andrew Spencer, H. Miles Prince, Kapil N. Bhalla, Thomas Fischer, Angela Liu, Kathryn Parker, Muhammad Jalaluddin, Glen Laird, Margaret Woo, Jeffrey W. Scott, Daniel J. DeAngelo
Journal: Blood
Blood (2008) 112 (11): 958.
https://doi.org/10.1182/blood.V112.11.958.958
Published: 2008
Journal Articles

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Andrew Spencer, MD, Miles Prince, MD, Daniel J. DeAngelo, MD, Thomas Fischer, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPa, Angela Liu, PharmD, Kathryn Parker, PhD, Glen Laird, PhD, Eric Masson, PharmD, John Rediske, PhD, Jeffrey W. Scott, PhD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2007) 110 (11): 907.
https://doi.org/10.1182/blood.V110.11.907.907
Published: 2007